Tag: Heart / Stroke-Related: High Cholesterol
About Half of Patients Receive Approval for PCSK9i Prescription
Prescription abandonment linked to copay costs, with rates more than 75 percent for copays > $350
Anagliptin Effect on LDL in T2DM Via ApoB-100 Synthesis
Improvement appears mediated, at least in part, through suppression of apoB-100 synthesis
Anacetrapib Linked to Lower Incidence of Coronary Events
Lower incidence versus placebo for patients with atherosclerotic vascular dz receiving intensive statins
More Evidence Evolocumab Exceeds Cost-Effectiveness
Findings for addition of evolocumab to standard tx in atherosclerotic cardiovascular disease
Cost-Effectiveness of PCSK9 Inhibitors Called Into Question
Researchers say price would have to be between $4,000 and $5,000 per year to be cost-effective
Evolocumab Doesn’t Affect Cognition When Added to Statins
No significant between-group difference for patients receiving evolocumab or placebo added to statins
Case Highlights Polygenic Risk in Severe Hypertriglyceridemia
Patient with hypertriglyceridemia had polymorphisms producing triglyceride risk score of 19
Replacing Saturated Fats With Healthy Fats Lowers CVD Risk
Healthy fats can help reduce risk of cardiovascular disease as effectively as statins, researchers say
Targeting ANGPTL3 Can Significantly Lower Cholesterol
Two trials show promise for non-statin approach to cardiovascular disease prevention
Findings Support More Targeted Approach to Cholesterol Screens
Among normotensive nonsmokers without diabetes, very few at heightened risk of ASCVD
